Wesbanco Bank Inc. reduced its stake in shares of Mylan NV (NASDAQ:MYL) by 12.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 35,313 shares of the company’s stock after selling 5,068 shares during the period. Wesbanco Bank Inc.’s holdings in Mylan were worth $968,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. First Hawaiian Bank lifted its stake in shares of Mylan by 560.4% during the fourth quarter. First Hawaiian Bank now owns 2,886 shares of the company’s stock worth $79,000 after buying an additional 2,449 shares during the period. NuWave Investment Management LLC lifted its stake in shares of Mylan by 18.1% during the fourth quarter. NuWave Investment Management LLC now owns 3,136 shares of the company’s stock worth $86,000 after buying an additional 480 shares during the period. FNY Investment Advisers LLC lifted its stake in shares of Mylan by 42.8% during the fourth quarter. FNY Investment Advisers LLC now owns 3,300 shares of the company’s stock worth $90,000 after buying an additional 989 shares during the period. Quantamental Technologies LLC acquired a new stake in shares of Mylan during the fourth quarter worth $100,000. Finally, Huntington National Bank lifted its stake in shares of Mylan by 200.4% during the fourth quarter. Huntington National Bank now owns 3,860 shares of the company’s stock worth $106,000 after buying an additional 2,575 shares during the period. Institutional investors and hedge funds own 83.16% of the company’s stock.
A number of research firms recently issued reports on MYL. Morgan Stanley boosted their target price on shares of Mylan from $36.00 to $39.00 and gave the company a “hold” rating in a research report on Tuesday, November 6th. Cowen set a $31.00 target price on shares of Mylan and gave the company a “hold” rating in a research report on Tuesday, November 6th. Cantor Fitzgerald restated a “hold” rating and set a $41.00 target price on shares of Mylan in a research report on Tuesday, November 20th. Argus upgraded shares of Mylan from a “hold” rating to a “buy” rating and set a $42.00 target price for the company in a research report on Thursday, November 15th. Finally, Mizuho restated a “neutral” rating on shares of Mylan in a research report on Thursday, January 31st. Two research analysts have rated the stock with a sell rating, six have given a hold rating and ten have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $42.86.
Shares of Mylan stock traded up $0.11 during trading hours on Monday, reaching $30.58. The stock had a trading volume of 52,744 shares, compared to its average volume of 4,321,085. The company has a market cap of $15.71 billion, a P/E ratio of 6.71, a price-to-earnings-growth ratio of 1.05 and a beta of 1.63. Mylan NV has a twelve month low of $26.03 and a twelve month high of $44.18. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.77 and a current ratio of 1.26.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.
Featured Story: What is Compound Interest?
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan NV (NASDAQ:MYL).
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.